SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northfield Lab(NFLD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (69)7/8/1998 6:35:00 PM
From: Merritt  Read Replies (1) of 148
 
V1, it looks that way to me, also...at least for now. In 2 or 3 years we may have a completely different picture and perception. In speaking with Biopure, I got a sense of excited anticipation, not so much for the use of Hemopure as a blood substitute, but as a way to use oxygen as a therapeutic, either by itself, or in combinational therapies. Until there's a proven product, which now seems very likely, scientists have been unable to conduct studies of the effects of elevated levels of oxygen in the body...so these new products will open a whole new field of study. Some of the research people seem to feel that it may have such significance as to, at some future date, actually change the basic concept of how physicians approach treating patients. Long way away, but apparently that's where Baxter has now switched their focus. Merritt
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News